State Street Corp Acquires 119,936 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

State Street Corp increased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,452,811 shares of the company’s stock after buying an additional 119,936 shares during the period. State Street Corp owned 0.05% of Krystal Biotech worth $264,455,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Hilltop Holdings Inc. bought a new stake in shares of Krystal Biotech during the third quarter worth approximately $209,000. Erste Asset Management GmbH acquired a new position in Krystal Biotech during the third quarter valued at approximately $3,224,000. Bellevue Group AG grew its holdings in Krystal Biotech by 13.8% during the third quarter. Bellevue Group AG now owns 4,779 shares of the company’s stock valued at $870,000 after purchasing an additional 581 shares during the period. Edgestream Partners L.P. acquired a new position in Krystal Biotech during the third quarter valued at approximately $5,872,000. Finally, Braidwell LP grew its holdings in Krystal Biotech by 57.4% during the third quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after purchasing an additional 61,512 shares during the period. 86.29% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Citigroup boosted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Stifel Nicolaus boosted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $202.29.

Krystal Biotech Stock Up 0.7 %

Krystal Biotech stock opened at $185.74 on Wednesday. The stock has a market capitalization of $5.34 billion, a PE ratio of 104.94 and a beta of 0.80. Krystal Biotech, Inc. has a twelve month low of $103.83 and a twelve month high of $219.34. The company has a 50 day moving average of $181.31 and a 200-day moving average of $184.78.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. During the same quarter in the prior year, the company posted ($0.67) earnings per share. The firm’s revenue was up 879.9% on a year-over-year basis. Equities analysts anticipate that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).